Hargreaves Lansdown

Optibiotix names René Kamminga as CEO of subsidiary

Tue 23 March 2021 08:06 | A A A

No recommendation

No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.

(Sharecast News) - Biotechnology company Optibiotix Health named René Kamminga as chief executive officer of its OptiBiotix Ltd subsidiary on Tuesday, subject to completion of normal regulatory due diligence.

Optibiotix said the appointment of Kamminga, formerly the chief commercial officer of KD Pharma's Nutraceuticals division, continued the evolution of its board and management team in line with its strategic focus on commercialising final products solutions and second-generation products.

The AIM-listed group added that Kamminga had experience in developing a business from selling bulk ingredients to finished product and a wealth of industry contacts in both the pharmaceutical and nutraceutical industries, as well as "a strong track record" of rapidly growing sales.

Elsewhere, Optibiotix said Dr Fred Narbel will move from his position as director on the OptiBiotix Health board and managing director of the functional fibres division of OptiBiotix Ltd to a more strategic role as non-executive director.

As of 1335 GMT, Optibiotix shares had dipped 0.23% to 51.88p.

    The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.


    More AIM news from ShareCast

    No results were found